Literature DB >> 20308568

HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma.

Henrik Hjalgrim1, Klaus Rostgaard, Paul C D Johnson, Annette Lake, Lesley Shield, Ann-Margaret Little, Karin Ekstrom-Smedby, Hans-Olov Adami, Bengt Glimelius, Stephen Hamilton-Dutoit, Eleanor Kane, G Malcolm Taylor, Alex McConnachie, Lars P Ryder, Christer Sundstrom, Paal Skytt Andersen, Ellen T Chang, Freda E Alexander, Mads Melbye, Ruth F Jarrett.   

Abstract

A proportion of classical Hodgkin lymphoma (HL) is believed to be causally related to infection with the ubiquitous lymphotropic EBV. The determining factors for development of EBV-related HL remain poorly understood, but likely involve immunological control of the viral infection. Accordingly, markers of the HLA class I region have been associated with risk of EBV-related HL. To study the host genetic component of EBV-related HL further, we investigated the lymphoma's association with HLA-A*01 and HLA-A*02 simultaneously in the setting of infectious mononucleosis (IM), a risk factor for EBV-related HL, in a case-series analysis including 278 EBV-related and 656 EBV-unrelated cases of HL. By logistic regression, HLA-A*01 alleles [odds ratio (OR) per allele, 2.15; 95% CI, 1.60-2.88] were associated with increased and HLA-A*02 alleles (OR per allele, 0.70; 95% CI, 0.51-0.97) with decreased risk of EBV-related HL. These allele-specific associations corresponded to nearly 10-fold variation in risk of EBV-related HL between HLA-A*01 and HLA-A*02 homozygotes. History of IM was also associated with risk of EBV-related HL (OR, 3.40; 95% CI, 1.74-6.66). The association between history of IM and EBV-related HL was not seen in the presence of HLA-A*02 because this allele appeared to neutralize the effect of IM on EBV-related HL risk. Our findings suggest that HLA class I-restricted EBV-specific cytotoxic T-cell responses and events in the early immune response to EBV infection in IM play critical roles in the pathogenesis of EBV-related HL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308568      PMCID: PMC2851961          DOI: 10.1073/pnas.0915054107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.

Authors:  L C Tan; N Gudgeon; N E Annels; P Hansasuta; C A O'Callaghan; S Rowland-Jones; A J McMichael; A B Rickinson; M F Callan
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

2.  Is EBV persistence in vivo a model for B cell homeostasis?

Authors:  G Khan; E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

3.  Determination of HLA-A*02 antigen status in Hodgkin's disease and analysis of an HLA-A*02-restricted epitope of the Epstein-Barr virus LMP-2 protein.

Authors:  H Bryden; J MacKenzie; L Andrew; F E Alexander; B Angus; A S Krajewski; A A Armstrong; D Gray; R A Cartwright; E Kane; D H Wright; P Taylor; R F Jarrett
Journal:  Int J Cancer       Date:  1997-08-07       Impact factor: 7.396

4.  Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA1): immunohistologic detection of EBNA1 in the malignant cells of Hodgkin's disease.

Authors:  F A Grässer; P G Murray; E Kremmer; K Klein; K Remberger; W Feiden; G Reynolds; G Niedobitek; L S Young; N Mueller-Lantzsch
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

5.  Ultraviolet radiation exposure and risk of malignant lymphomas.

Authors:  Karin Ekström Smedby; Henrik Hjalgrim; Mads Melbye; Anna Torrång; Klaus Rostgaard; Lars Munksgaard; Johanna Adami; Mads Hansen; Anna Porwit-MacDonald; Bjarne Anker Jensen; Göran Roos; Bjarne Bach Pedersen; Christer Sundström; Bengt Glimelius; Hans-Olov Adami
Journal:  J Natl Cancer Inst       Date:  2005-02-02       Impact factor: 13.506

6.  Exposure to childhood infections and risk of Epstein-Barr virus--defined Hodgkin's lymphoma in women.

Authors:  Sally L Glaser; Theresa H M Keegan; Christina A Clarke; Muoi Trinh; Ronald F Dorfman; Risa B Mann; Joseph A DiGiuseppe; Richard F Ambinder
Journal:  Int J Cancer       Date:  2005-07-01       Impact factor: 7.396

Review 7.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

8.  HLA class I (A, B) and II (DR, DQ) gene and haplotype frequencies in blood donors from Wales.

Authors:  C Darke; M G Guttridge; J Thompson; S McNamara; J Street; M Thomas
Journal:  Exp Clin Immunogenet       Date:  1998

9.  Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease.

Authors:  P G Murray; C M Constandinou; J Crocker; L S Young; R F Ambinder
Journal:  Blood       Date:  1998-10-01       Impact factor: 22.113

10.  Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease.

Authors:  H Herbst; H D Foss; J Samol; I Araujo; H Klotzbach; H Krause; A Agathanggelou; G Niedobitek; H Stein
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

View more
  38 in total

Review 1.  Familial predisposition and genetic risk factors for lymphoma.

Authors:  James R Cerhan; Susan L Slager
Journal:  Blood       Date:  2015-09-24       Impact factor: 22.113

Review 2.  Viruses and human cancer: from detection to causality.

Authors:  Ronit Sarid; Shou-Jiang Gao
Journal:  Cancer Lett       Date:  2010-10-23       Impact factor: 8.679

Review 3.  Progress, prospects, and problems in Epstein-Barr virus vaccine development.

Authors:  Henry H Balfour
Journal:  Curr Opin Virol       Date:  2014-03-15       Impact factor: 7.090

Review 4.  Hodgkin lymphoma.

Authors:  Joseph M Connors; Wendy Cozen; Christian Steidl; Antonino Carbone; Richard T Hoppe; Hans-Henning Flechtner; Nancy L Bartlett
Journal:  Nat Rev Dis Primers       Date:  2020-07-23       Impact factor: 52.329

5.  Epstein-Barr virus: an important vaccine target for cancer prevention.

Authors:  Jeffrey I Cohen; Anthony S Fauci; Harold Varmus; Gary J Nabel
Journal:  Sci Transl Med       Date:  2011-11-02       Impact factor: 17.956

6.  Evidence of genetic susceptibility to infectious mononucleosis: a twin study.

Authors:  A E Hwang; A S Hamilton; M G Cockburn; R Ambinder; J Zadnick; E E Brown; T M Mack; W Cozen
Journal:  Epidemiol Infect       Date:  2011-12-08       Impact factor: 2.451

7.  Association of HLA polymorphisms with post-transplant lymphoproliferative disorder in solid-organ transplant recipients.

Authors:  R Reshef; M R Luskin; M Kamoun; S Vardhanabhuti; J E Tomaszewski; E A Stadtmauer; D L Porter; D F Heitjan; De E Tsai
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

8.  T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications.

Authors:  Claudio Fozza; Maurizio Longinotti
Journal:  Adv Hematol       Date:  2010-10-12

Review 9.  Epstein-Barr virus: more than 50 years old and still providing surprises.

Authors:  Lawrence S Young; Lee Fah Yap; Paul G Murray
Journal:  Nat Rev Cancer       Date:  2016-09-30       Impact factor: 60.716

10.  DNA methylation patterns of adult survivors of adolescent/young adult Hodgkin lymphoma compared to their unaffected monozygotic twin.

Authors:  Jun Wang; David Van Den Berg; Amie E Hwang; Daniel Weisenberger; Timothy Triche; Bharat N Nathwani; David V Conti; Kim Siegmund; Thomas M Mack; Steve Horvath; Wendy Cozen
Journal:  Leuk Lymphoma       Date:  2019-01-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.